Michelle T. Long, MD, MSc

Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Michelle T. Long, MD, MSc is a physician-scientist with an expertise in Nonalcoholic fatty liver disease (NAFLD), and an Associate Professor of Medicine at Boston University. She completed her clinical training at Massachusetts General Hospital and Boston Medical Center. Dr. Long is the Director of the NAFLD Research Center and the Director of Clinical Research for the Section of Gastroenterology and Hepatology. Her clinical and research interests center on the relationship between NAFLD and cardiovascular disease. Dr. Long is primarily interested in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD and in imaging and risk stratification strategies for hepatic fibrosis. Dr. Long has projects at Boston Medical Center and at the Framingham Heart Study where she is the PI of a study evaluating the prevalence and risk factors for liver fat (steatosis) and fibrosis. In Framingham, she is investigating the clinical and genetic correlates of hepatic steatosis and fibrosis as measured by transient elastography. Dr. Long receives research funding from the NIH (NIDDK), Doris Duke Charitable Foundation, Gilead Sciences, Echosens Corporation, and Boston University. She has expertise in epidemiology, visceral fat, liver imaging including computed tomography, ultrasound, and transient elastography. Dr. Long is also a clinical hepatologist and endoscopist.

Dr. Long is additionally interested in novel therapeutics for NAFLD and Non-alcoholic steatohepatitis (NASH) and runs the clinical trials program for the NAFLD Research Center.

Her other research interests include alcohol-related liver disease, hepatitis C, outcomes in end-stage liver disease/cirrhosis.

Publications

  • Published 5/15/2025

    El-Sabawi B, Tanriverdi K, Gajjar P, Nayor M, Landman JM, Below JE, Haff M, Long M, Ezpeleta M, Freedman JE, Varady K, Shah R, Perry AS. Circulating Proteomics Identifies a Dynamic Profile of Hepatic Steatosis During Metabolic Intervention. J Am Heart Assoc. 2025 May 15; e037100. PMID: 40371575.

    Read at: PubMed

  • Published 4/25/2025

    Mohanty A, Austad K, Bosch NA, Long MT, Nolen-Doerr E, Walkey AJ, Drainoni ML, Rizo I, Fantasia KL. Assessing Clinician Engagement with a Passive Clinical Decision Support System for Liver Fibrosis Risk Stratification in a Weight Management Clinic. Endocr Pract. 2025 Apr 25. PMID: 40288606.

    Read at: PubMed

  • Published 4/21/2025

    Newsome P, Sanyal A, Kliers I, Østergaard L, Long M, Kjær M, Cali AMG, Bugianesi E, Rinella M, Roden M, Ratziu V. Erratum: Late breaking abstracts. Hepatology. 2025 Apr 21. PMID: 40258120.

    Read at: PubMed

  • Published 2/11/2025

    Fuster D, So-Armah K, Cheng DM, Blokhina E, Patts G, Lioznov D, Gnatienko N, Long MT, Freiberg MS, Tindle H, Samet JH. Is There an Association Between Cigarette Smoking and Advanced Liver Fibrosis in Smokers with HIV, Heavy Drinking and High Prevalence of HCV? J Clin Med. 2025 Feb 11; 14(4). PMID: 40004700.

    Read at: PubMed

  • Published 1/27/2025

    Sun N, Prescott B, Ma J, Xanthakis V, Quatromoni PA, Long MT, Walker ME. The cross-sectional association between ultra-processed food intake and metabolic dysfunction-associated steatotic liver disease. Clin Nutr ESPEN. 2025 Apr; 66:215-220. PMID: 39880205.

    Read at: PubMed

View All 100 Publications:   View Full Profile in BUMC

Other Positions

  • Associate Professor, Medicine
    Boston University Chobanian & Avedisian School of Medicine
  • Investigator
    Framingham Heart Study
  • Member, Evans Center for Interdisciplinary Biomedical Research
    Boston University
  • Full Member, Boston Nutrition Obesity Research Center
    Boston University Medical Center

Websites

Education

  • Tufts University School of Medicine, MD
  • Boston University School of Public Health, MSc
  • Middlebury College, BA

View all profiles